With ongoing trials of SP-A peptides to treat asthma and the use of SP-A peptides to treat RSV (97–99) the present findings point to a future need to investigate SP-A as adjunct therapeutic modality for RDS as well. The gene discussed is SFTPA1; the disease is asthma.